Proposed Bill Targets Prostate Cancer Misdiagnoses

Legislation would authorize CMS to pay for backup DNA tests

Deepak A. Kapoor, MD, chairman and CEO, Integrated Medical Professionals, Melville, NY, told the Energy and Commerce Committee that a 2015 study found that misdiagnoses based on needle biopsies occurred in 2.5% of cases and would largely be eliminated if the backup DNA test became standard practice (J Urol 2015; 193:1170-7). The study concluded that at least 1.28% of those patients were actually cancer free.

Dr. Kapoor is health policy chair at LUGPA, which along with the AUA, the Men’s Health Network, the Prostate Health Education Network, and several other related groups have endorsed the legislation. Read about the bill and how it benefits patients here.

This entry was posted in News. Bookmark the permalink.